Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Novartis AG (NVS) Price & Performance

GXO Logistics IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Novartis AG — how do they compare? GXO Logistics Inc trades at $54.2 (market cap $6.02B), while Novartis AG trades at $150.91 (market cap $287.66B). The key difference: Novartis AG is far larger — about 47.8× GXO Logistics Inc's market cap, and Novartis AG pays a 3.14% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.

GXONVS
Market Cap
$6.02B$287.66B
Sector
IndustrialsHealth
52-Week High
$65.59$168.62
52-Week Low
$45.52$113.50
Enterprise Value
$11.18B$327.68B
Dividend Yield
3.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO Logistics is trading at $53.36, up 7.43% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamental performance with three consecutive quarterly earnings beats and 10.8% revenue growth in Q1 2026. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $66.60 consensus price target representing 25% upside potential. Recent business developments include multiple partnership renewals and expansion into strategic verticals like aerospace and defense.

GXO presents a compelling investment opportunity with strong earnings momentum and institutional support, though investors should monitor competitive pressures from Amazon's logistics expansion and the company's transition toward higher-margin verticals. The stock's current valuation at 46.69x P/E appears elevated relative to modest net margins, requiring continued execution on growth initiatives to justify premium multiples.

Novartis AG

NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).

The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS